The formation of tissue adhesions is a frequent consequence following surgical interventions. The adhesions occur as a result of adjacent internal organs coming into contact and forming fibrous tissue between them. Adhesion formation triggers a series of biological processes, including an acute inflammatory response due to damage to the peritoneal mesothelium. This inflammation encourages the growth of fibrous adhesions, which can cause various post-operative symptoms, such as chronic pelvic pain, bowel obstruction, restricted movement, dyspareunia, infertility, and a higher complication risk in subsequent operations. As a result, a second surgical procedure may be necessary to remove fibrous tissue. To ensure optimal surgical outcomes and prevent the development of post-surgical adhesions, it is advisable to employ Hillaria®. Hillaria® is a viscous gel with high transparency and biodegradability. This sterile gel is produced by crosslinking a unique type of Hyaluronic acid, which is a fundamental component of human connective tissue as well as epithelial and mesothelial tissue. Hillaria® has the capability of adhering to tissue surfaces and the abdominal wall, thereby creating a barrier that effectively prevents the formation of tissue adhesions. The indications of Hillaria® include its use in abdominal interventions, whether performed through laparotomy or laparoscopy, as well as in hysteroscopic procedures. Its primary purpose is to reduce the formation of adhesions subsequent to surgery. Each package of Hillaria® contains two sterile syringes of 5 ml (each mL provides 20 mg of cross-linked Hyaluronic Acid and 2 mg of Hyaluronic Acid), a leaflet and a set of tracking labels.